Delcath Systems vs Pulse Biosciences
Delcath Systems reported revenue of $85 million in fiscal 2025, 284.0 times Pulse Biosciences' $0 million in fiscal 2025. Delcath Systems had an operating margin of 0.8%, against -21982.6% at Pulse Biosciences. Free cash flow was $21 million at Delcath Systems and −$54 million at Pulse Biosciences.
Side by side
| Delcath Systems | Pulse Biosciences | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $85M | $0M |
| Revenue growth | 129.1% | — |
| Revenue growth a year, last 5 years | — | — |
| Gross margin | 86.2% | −54.0% |
| Operating margin | 0.8% | −21,982.6% |
| Net margin | 3.2% | −20,794.6% |
| Free cash flow | $21M | −$54M |
| Free cash flow margin | 24.6% | −15,553.4% |
| Return on capital | 2.8% | — |
| Net debt to EBITDA | −101.4x | — |
| Dividends and buybacks | $6M | $0M |
| Change in diluted share count | 40.0% | 15.4% |
| Last close | $20.55 | $50.44 |
| P/E at the last close | 128.4× | — |
| Insider trades, last 12 months | — | — |
| Piotroski F-score | 6 of 9 | 3 of 8 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Delcath SystemsPulse Biosciences
Operating margin
Percent of revenue
Delcath SystemsPulse Biosciences
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Delcath SystemsPulse Biosciences
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Delcath Systems and Pulse Biosciences pages.